Methods of administering genetically modified b cells for in vivo delivery of therapeutic agents

Abstract

Provided herein are methods for administering engineered B cells to produce a therapeutic agent in vivo. In various embodiments, engineered B cells are directly administered to the central nervous system (CNS). The compositions and methods disclosed herein may be used for enzyme replacement therapy, for example, treatment of diseases or disorders associated with lysosomal storage dysfunction through production of iduronidase (IDUA).

Dependencies are inferred from the claim text.